Literature DB >> 24166024

Role of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of the pancreas.

Hyo Jun Park1, Dong Do You, Dong Wook Choi, Jin Seok Heo, Seong Ho Choi.   

Abstract

BACKGROUND: Studies have claimed that in the surgical treatment of pancreas body and tail cancer, radical antegrade modular pancreatosplenectomy (RAMPS) is associated with effective tangential margin and extensive lymph node dissection. In the present study, the authors have compared the surgical outcomes between RAMPS and conventional distal pancreatosplenectomy (DPS) in patients with adenocarcinoma of the pancreas body and tail, and also identified prognostic factors associated with survival after surgery.
METHODS: Retrospective review of 92 consecutive patients who underwent surgical resection for pancreas body and tail adenocarcinoma with curative intent between 1995 and 2010. Median follow-up duration was 16.1 months.
RESULTS: Of the 92 patients, 38 patients received RAMPS and 54 patients received DPS. Patients who underwent RAMPS had a greater number of retrieved lymph nodes than patients undergoing DPS [median 14 (5-52) vs. 9 (1-36), p < 0.05]. Conventional DPS, no adjuvant chemoradiation therapy (CRT), and non-curative resection were associated with poor overall survival (OS) on univariate analysis. After multivariate analysis for these variables, only the lack of adjuvant CRT and resection margin status were found to adversely affect OS.
CONCLUSIONS: While the RAMPS procedure is effective in performing an extensive LN dissection, it is not associated with better retroperitoneal resection margin or retrieval of more positive LNs, and it does not lead to better curability or OS survival compared to DPS. Lack of adjuvant CRT and resection margin status are poor prognostic factors in patients with pancreas body and tail cancer.

Entities:  

Mesh:

Year:  2014        PMID: 24166024     DOI: 10.1007/s00268-013-2254-8

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  24 in total

1.  Long-term survival after pancreatoduodenectomy for ductal adenocarcinoma: the emperor has no clothes?

Authors:  Edward L Bradley
Journal:  Pancreas       Date:  2008-11       Impact factor: 3.327

2.  Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.

Authors:  J P Neoptolemos; J A Dunn; D D Stocken; J Almond; K Link; H Beger; C Bassi; M Falconi; P Pederzoli; C Dervenis; L Fernandez-Cruz; F Lacaine; A Pap; D Spooner; D J Kerr; H Friess; M W Büchler
Journal:  Lancet       Date:  2001-11-10       Impact factor: 79.321

3.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

Authors:  J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

4.  Improved survival of left-sided pancreas cancer after surgery.

Authors:  Junji Yamamoto; Akio Saiura; Rintaro Koga; Makoto Seki; Masamichi Katori; Yo Kato; Yosihiro Sakamoto; Norihiro Kokudo; Toshiharu Yamaguchi
Journal:  Jpn J Clin Oncol       Date:  2010-04-02       Impact factor: 3.019

5.  Resection for adenocarcinoma of the body and tail of the pancreas.

Authors:  C D Johnson; G Schwall; J Flechtenmacher; M Trede
Journal:  Br J Surg       Date:  1993-09       Impact factor: 6.939

6.  En bloc resection for locally advanced cancer of the pancreas: is it worthwhile?

Authors:  Aaron R Sasson; John P Hoffman; Eric A Ross; Steven A Kagan; James F Pingpank; Burton L Eisenberg
Journal:  J Gastrointest Surg       Date:  2002 Mar-Apr       Impact factor: 3.452

7.  Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients.

Authors:  Jonathan E Lim; Michael W Chien; Craig C Earle
Journal:  Ann Surg       Date:  2003-01       Impact factor: 12.969

8.  Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.

Authors:  Dong Do You; Hyung Geun Lee; Jin Seok Heo; Seong Ho Choi; Dong Wook Choi
Journal:  J Gastrointest Surg       Date:  2009-07-07       Impact factor: 3.452

9.  Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients.

Authors:  C J Yeo; J L Cameron; K D Lillemoe; J V Sitzmann; R H Hruban; S N Goodman; W C Dooley; J Coleman; H A Pitt
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

10.  Is extended resection for adenocarcinoma of the body or tail of the pancreas justified?

Authors:  Margo Shoup; Kevin C Conlon; David Klimstra; Murray F Brennan
Journal:  J Gastrointest Surg       Date:  2003-12       Impact factor: 3.267

View more
  18 in total

1.  Pan-European survey on the implementation of minimally invasive pancreatic surgery with emphasis on cancer.

Authors:  Thijs de Rooij; Marc G Besselink; Awad Shamali; Giovanni Butturini; Olivier R Busch; Bjørn Edwin; Roberto Troisi; Laureano Fernández-Cruz; Ibrahim Dagher; Claudio Bassi; Mohammad Abu Hilal
Journal:  HPB (Oxford)       Date:  2015-12-10       Impact factor: 3.647

Review 2.  No-touch isolation techniques for pancreatic cancer.

Authors:  Tamotsu Kuroki; Susumu Eguchi
Journal:  Surg Today       Date:  2016-03-01       Impact factor: 2.549

3.  Comparison of minimal invasive versus open radical antegrade modular pancreatosplenectomy (RAMPS) for pancreatic ductal adenocarcinoma: a single center retrospective study.

Authors:  Hanyu Zhang; Yatong Li; Quan Liao; Cheng Xing; Cheng Ding; Taiping Zhang; Junchao Guo; Xianlin Han; Qiang Xu; Wenming Wu; Yupei Zhao; Menghua Dai
Journal:  Surg Endosc       Date:  2020-10-08       Impact factor: 4.584

4.  Laparoscopic surgery for pancreatic neoplasms: the European association for endoscopic surgery clinical consensus conference.

Authors:  Bjørn Edwin; Mushegh A Sahakyan; Mohammad Abu Hilal; Marc G Besselink; Marco Braga; Jean-Michel Fabre; Laureano Fernández-Cruz; Brice Gayet; Song Cheol Kim; Igor E Khatkov
Journal:  Surg Endosc       Date:  2017-02-15       Impact factor: 4.584

5.  Complications in Distal Pancreatectomy versus Radical Antegrade Modular Pancreatosplenectomy: A Disease Risk Score Analysis Utilizing National Surgical Quality Improvement Project Data.

Authors:  Thomas L Sutton; Kristin C Potter; Skye C Mayo; Rodney Pommier; Erin W Gilbert; Brett C Sheppard
Journal:  World J Surg       Date:  2022-04-11       Impact factor: 3.282

6.  Comparison of Surgical Outcomes Between Radical Antegrade Modular Pancreatosplenectomy (RAMPS) and Standard Retrograde Pancreatosplenectomy (SPRS) for Left-Sided Pancreatic Cancer.

Authors:  Toshiya Abe; Kenoki Ohuchida; Yoshihiro Miyasaka; Takao Ohtsuka; Yoshinao Oda; Masafumi Nakamura
Journal:  World J Surg       Date:  2016-09       Impact factor: 3.352

Review 7.  Laparoscopic distal pancreatectomy for adenocarcinoma: safe and reasonable?

Authors:  Lauren M Postlewait; David A Kooby
Journal:  J Gastrointest Oncol       Date:  2015-08

8.  Prognostic stratification based on a novel nomogram for left-sided pancreatic adenocarcinoma after surgical resection: a multi-center study.

Authors:  Zuyi Ma; Bowen Huang; Shanzhou Huang; Chunsheng Liu; Jiasheng Cao; Zehao Zheng; Zhenchong Li; Zixuan Zhou; Hongkai Zhuang; Yiping Zou; Linling Yang; Junchao Guo; Chuanzhao Zhang; Baohua Hou
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

9.  Radical antegrade modular pancreatosplenectomy (RAMPS) versus conventional distal pancreatectomy for left-sided pancreatic cancer: findings of a multicenter, retrospective, propensity score matching study.

Authors:  Hyung Sun Kim; Tae Ho Hong; Young-Kyoung You; Joon Seong Park; Dong Sup Yoon
Journal:  Surg Today       Date:  2021-04-08       Impact factor: 2.549

10.  The short- and long-term outcomes of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of the pancreas.

Authors:  Masaaki Murakawa; Toru Aoyama; Masahiro Asari; Yusuke Katayama; Koichiro Yamaoku; Amane Kanazawa; Akio Higuchi; Manabu Shiozawa; Satoshi Kobayashi; Makoto Ueno; Manabu Morimoto; Naoto Yamamoto; Takaki Yoshikawa; Yasushi Rino; Munetaka Masuda; Soichiro Morinaga
Journal:  BMC Surg       Date:  2015-10-30       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.